当前位置：　期刊中心 > 期刊介绍 > 分子癌症治疗

期刊中心

Molecular Cancer Therapeutics
(MOL CANCER THER) 《分子癌症治疗》

网友评分点击次数：145
分子癌症治疗
2011年影响因子
5.226
推荐阅读

全球精选全文

更多
目录导读
Published 2012年8月,Volume 11,Issue 8

最新一期

Highlights

  • Highlights of This Issue

    Mol Cancer Ther August 2012 11:1619
    • Full Text
    •  
    • Full Text (PDF)

Editorial

  • Toward a New Era in Cancer Treatment: Message from the New Editor-in-Chief

    • John C. Reed, MD, PhD
    Mol Cancer Ther August 2012 11:1621-1622; doi:10.1158/1535-7163.MCT-12-0703
    • Full Text
    •  
    • Full Text (PDF)

Spotlight in Clinical Response

  • Sustained Remission of Multicentric Castleman Disease in Children Treated with Tocilizumab, an Anti-Interleukin-6 Receptor Antibody

    • Caroline Galeotti, 
    • Adeline Boucheron, 
    • Séverine Guillaume, 
    • and Isabelle Koné-Paut
    Mol Cancer Ther August 2012 11:1623-1626; Published OnlineFirst May 25, 2012;doi:10.1158/1535-7163.MCT-11-0972
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
 

Review

  • DNA Damage Repair Pathways in Cancer Stem Cells

    • Marcello Maugeri-Saccà, 
    • Monica Bartucci, 
    • and Ruggero De Maria
    Mol Cancer Ther August 2012 11:1627-1636; Published OnlineFirst July 25, 2012;doi:10.1158/1535-7163.MCT-11-1040
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
 

Therapeutic Discovery

  • SAR131675, a Potent and Selective VEGFR-3–TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities

    • Antoine Alam, 
    • Isabelle Blanc, 
    • Geneviève Gueguen-Dorbes, 
    • Olivier Duclos,
    • Jacques Bonnin, 
    • Pauline Barron, 
    • Marie-Claude Laplace, 
    • Gaelle Morin,
    • Florence Gaujarengues, 
    • Frédérique Dol, 
    • Jean-Pascal Hérault, 
    • Paul Schaeffer,
    • Pierre Savi, 
    • and Françoise Bono
    Mol Cancer Ther August 2012 11:1637-1649; Published OnlineFirst May 14, 2012;doi:10.1158/1535-7163.MCT-11-0866-T
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

    • David W. Jenkins, 
    • Sarah Ross, 
    • Margaret Veldman-Jones, 
    • Ian N. Foltz,
    • Brandon C. Clavette, 
    • Kathy Manchulenko, 
    • Cath Eberlein, 
    • Jane Kendrew,
    • Philip Petteruti, 
    • Song Cho, 
    • Melissa Damschroder, 
    • Li Peng, 
    • Dawn Baker,
    • Neil R. Smith, 
    • Hazel M. Weir, 
    • David C. Blakey, 
    • Vahe Bedian, 
    • and Simon T. Barry
    Mol Cancer Ther August 2012 11:1650-1660; Published OnlineFirst June 7, 2012;doi:10.1158/1535-7163.MCT-11-1027
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data
    Free Article

  • Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer

    • Masafumi Kumano, 
    • Junya Furukawa, 
    • Masaki Shiota, 
    • Anousheh Zardan, 
    • Fan Zhang,
    • Eliana Beraldi, 
    • Romina M. Wiedmann, 
    • Ladan Fazli, 
    • Amina Zoubeidi,
    • and Martin E. Gleave
    Mol Cancer Ther August 2012 11:1661-1671; Published OnlineFirst June 6, 2012;doi:10.1158/1535-7163.MCT-12-0072
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitroand In Vivo

    • Yi Liu, 
    • Yanyan Cao, 
    • Weihe Zhang, 
    • Stephen Bergmeier, 
    • Yanrong Qian,
    • Huzoor Akbar, 
    • Robert Colvin, 
    • Juan Ding, 
    • Lingying Tong, 
    • Shiyong Wu,
    • Jennifer Hines, 
    • and Xiaozhuo Chen
    Mol Cancer Ther August 2012 11:1672-1682; Published OnlineFirst June 11, 2012;doi:10.1158/1535-7163.MCT-12-0131
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype

    • Campbell McInnes, 
    • Kara Estes, 
    • Merissa Baxter, 
    • Zhengguan Yang,
    • Doaa Boshra Farag, 
    • Paul Johnston, 
    • John S. Lazo, 
    • Jianjun Wang,
    • and Michael D. Wyatt
    Mol Cancer Ther August 2012 11:1683-1692; Published OnlineFirst July 30, 2012;doi:10.1158/1535-7163.MCT-12-0006-T
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib

    • Yinxiang Wei, 
    • Yuanfang Ma, 
    • Qing Zhao, 
    • Zhiguang Ren, 
    • Yan Li, 
    • Tingjun Hou,
    • and Hui Peng
    Mol Cancer Ther August 2012 11:1693-1702; Published OnlineFirst May 16, 2012;doi:10.1158/1535-7163.MCT-12-0215
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide

    • Yi-Te Yo, 
    • Ya-Wen Lin, 
    • Yu-Chi Wang, 
    • Curt Balch, 
    • Rui-Lan Huang,
    • Michael W.Y. Chan, 
    • Huey-Kang Sytwu, 
    • Chi-Kuan Chen, 
    • Cheng-Chang Chang,
    • Kenneth P. Nephew, 
    • Tim Huang, 
    • Mu-Hsien Yu, 
    • and Hung-Cheng Lai
    Mol Cancer Ther August 2012 11:1703-1712; Published OnlineFirst May 10, 2012;doi:10.1158/1535-7163.MCT-12-0002
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data
 

Preclinical Development

  • REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma

    • Pete Taylor, 
    • Jason Fangusaro, 
    • Veena Rajaram, 
    • Stewart Goldman,
    • Irene B. Helenowski, 
    • Tobey MacDonald, 
    • Martin Hasselblatt, 
    • Lars Riedemann,
    • Alvaro Laureano, 
    • Laurence Cooper, 
    • and Vidya Gopalakrishnan
    Mol Cancer Ther August 2012 11:1713-1723; Published OnlineFirst July 30, 2012;doi:10.1158/1535-7163.MCT-11-0990
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells

    • Wendy L. Allen, 
    • Richard C. Turkington, 
    • Leanne Stevenson, 
    • Gail Carson,
    • Vicky M. Coyle, 
    • Suzanne Hector, 
    • Philip Dunne, 
    • Sandra Van Schaeybroeck,
    • Daniel B. Longley, 
    • and Patrick G. Johnston
    Mol Cancer Ther August 2012 11:1724-1734; Published OnlineFirst June 4, 2012;doi:10.1158/1535-7163.MCT-12-0207
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells

    • Amir Avan, 
    • Francesco Crea, 
    • Elisa Paolicchi, 
    • Niccola Funel, 
    • Elena Galvani,
    • Victor E Marquez, 
    • Richard J. Honeywell, 
    • Romano Danesi, 
    • Godefridus J. Peters,
    • and Elisa Giovannetti
    Mol Cancer Ther August 2012 11:1735-1746; Published OnlineFirst May 23, 2012;doi:10.1158/1535-7163.MCT-12-0037
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

    • Saskia M. Brachmann, 
    • Julia Kleylein-Sohn, 
    • Swann Gaulis, 
    • Audrey Kauffmann,
    • Marcel J.J. Blommers, 
    • Malika Kazic-Legueux, 
    • Laurent Laborde, 
    • Marc Hattenberger,
    • Fabian Stauffer, 
    • Juliane Vaxelaire, 
    • Vincent Romanet, 
    • Chrystèle Henry,
    • Masato Murakami, 
    • Daniel Alexander Guthy, 
    • Dario Sterker, 
    • Sebastian Bergling,
    • Christopher Wilson, 
    • Thomas Brümmendorf, 
    • Christine Fritsch,
    • Carlos Garcia-Echeverria, 
    • William R. Sellers, 
    • Francesco Hofmann,
    • and Sauveur-Michel Maira
    Mol Cancer Ther August 2012 11:1747-1757; Published OnlineFirst May 31, 2012;doi:10.1158/1535-7163.MCT-11-1021
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors

    • Markus P. Ghadimi, 
    • Gonzalo Lopez, 
    • Keila E. Torres, 
    • Roman Belousov,
    • Eric D. Young, 
    • Jeffery Liu, 
    • Kari J. Brewer, 
    • Aviad Hoffman, 
    • Kristelle Lusby,
    • Alexander J. Lazar, 
    • Raphael E. Pollock, 
    • and Dina Lev
    Mol Cancer Ther August 2012 11:1758-1769; Published OnlineFirst July 30, 2012;doi:10.1158/1535-7163.MCT-12-0015
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors

    • Michael C. Heinrich, 
    • Adrian Marino-Enriquez, 
    • Ajia Presnell, 
    • Rachel S. Donsky,
    • Diana J. Griffith, 
    • Arin McKinley, 
    • Janice Patterson, 
    • Takahiro Taguchi,
    • Cher-Wei Liang, 
    • and Jonathan A. Fletcher
    Mol Cancer Ther August 2012 11:1770-1780; Published OnlineFirst June 4, 2012;doi:10.1158/1535-7163.MCT-12-0223
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only

  • The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells

    • Heather J. Landau, 
    • Samuel C. McNeely, 
    • Jayasree S. Nair, 
    • Raymond L. Comenzo,
    • Takashi Asai, 
    • Hillel Friedman, 
    • Suresh C. Jhanwar, 
    • Stephen D. Nimer,
    • and Gary K. Schwartz
    Mol Cancer Ther August 2012 11:1781-1788; Published OnlineFirst May 31, 2012;doi:10.1158/1535-7163.MCT-11-0949
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

    • Joanne M. Munck, 
    • Michael A. Batey, 
    • Yan Zhao, 
    • Helen Jenkins,
    • Caroline J. Richardson, 
    • Celine Cano, 
    • Michele Tavecchio, 
    • Jody Barbeau,
    • Julia Bardos, 
    • Liam Cornell, 
    • Roger J. Griffin, 
    • Keith Menear, 
    • Andrew Slade,
    • Pia Thommes, 
    • Niall M.B. Martin, 
    • David R. Newell, 
    • Graeme C.M. Smith,
    • and Nicola J. Curtin
    Mol Cancer Ther August 2012 11:1789-1798; Published OnlineFirst May 10, 2012;doi:10.1158/1535-7163.MCT-11-0535
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

    • Tomoko Smyth, 
    • Thomas Van Looy, 
    • Jayne E. Curry, 
    • Ana M. Rodriguez-Lopez,
    • Agnieszka Wozniak, 
    • Meijun Zhu, 
    • Rachel Donsky, 
    • Jennifer G. Morgan,
    • Mark Mayeda, 
    • Jonathan A. Fletcher, 
    • Patrick Schöffski, 
    • John Lyons,
    • Neil T. Thompson, 
    • and Nicola G. Wallis
    Mol Cancer Ther August 2012 11:1799-1808; Published OnlineFirst June 19, 2012;doi:10.1158/1535-7163.MCT-11-1046
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data

  • CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma

    • Licun Wu, 
    • Zhihong Yun, 
    • Tetsuzo Tagawa, 
    • Katrina Rey-McIntyre, 
    • and Marc de Perrot
    Mol Cancer Ther August 2012 11:1809-1819; Published OnlineFirst May 14, 2012;doi:10.1158/1535-7163.MCT-11-1014
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only
    •  
    • Supplementary Data
 

Molecular Medicine in Practice

  • Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors

    • Howard A. Burris III, 
    • Afshin Dowlati, 
    • Rebecca A. Moss, 
    • Jeffrey R. Infante,
    • Suzanne F. Jones, 
    • David R. Spigel, 
    • Kelly T. Levinson, 
    • Diana Lindquist,
    • Shelby D. Gainer, 
    • Mohammed M. Dar, 
    • A. Benjamin Suttle, 
    • Howard A. Ball,
    • and Antoinette R. Tan
    Mol Cancer Ther August 2012 11:1820-1828; Published OnlineFirst June 7, 2012;doi:10.1158/1535-7163.MCT-11-0997
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only

  • Inhibition of Dendritic Cell Maturation by the Tumor Microenvironment Correlates with the Survival of Colorectal Cancer Patients following Bevacizumab Treatment

    • Adriana J. Michielsen, 
    • Sinead Noonan, 
    • Petra Martin, 
    • Miriam Tosetto, 
    • Joseph Marry,
    • Monika Biniecka, 
    • Aoife A. Maguire, 
    • John M. Hyland, 
    • Kieran D. Sheahan,
    • Diarmuid P. O'Donoghue, 
    • Hugh E. Mulcahy, 
    • David Fennelly, 
    • Elizabeth J. Ryan,
    • and Jacintha N. O'Sullivan
    Mol Cancer Ther August 2012 11:1829-1837; Published OnlineFirst June 6, 2012;doi:10.1158/1535-7163.MCT-12-0162
    • Abstract
    •  
    • Full Text
    •  
    • Full Text (PDF)
    •  
    • Figures Only

过刊浏览

发表评论网友评论(13)

    审稿周期： 投稿难度：
    发表评论
    MOL CANCER THER 分子癌症治疗
    ISSN：
    1535-7163
    出版商：
    AMER ASSOC CANCER RE
    每年出版：
    12 期
    在线投稿
    最新一期内容
    • 期刊介绍
    • 英文介绍
    《分子癌症治疗》出版治疗发现，临床前开发，实践分子医学类别中最好的科学。该杂志为专门聚焦于癌症研究的这些新兴的学科提供了一个出版物论坛。论文严格审查，只有那些新颖，及时和重要的研究和满足高标准的科学价值将接受出版。
    Molecular Cancer Therapeutics publishes the best science in the categories of Therapeutic Discovery, Preclinical Development, and Molecular Medicine in Practice. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.
    更多>

    同类期刊影响因子排行

    刊名　　　　　　　　　　　　　　分值